Autoantibodies to type I interferons in patients with systemic mastocytosis

Autoantibodies to type I interferons have been identified in association with a variety of inflammatory and autoimmune diseases. Type I interferons have demonstrated inhibitory effects on mast cell proliferation and degranulation. Systemic mastocytosis (SM) is a disease characterized by increased ma...

Full description

Saved in:
Bibliographic Details
Published inThe journal of allergy and clinical immunology. Global Vol. 3; no. 3; p. 100273
Main Authors Cao, Vivian, Lee, Serena J., Bai, Yun, Holland, Steven M., Rosen, Lindsey B., Metcalfe, Dean D., Komarow, Hirsh D.
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.08.2024
Elsevier
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Autoantibodies to type I interferons have been identified in association with a variety of inflammatory and autoimmune diseases. Type I interferons have demonstrated inhibitory effects on mast cell proliferation and degranulation. Systemic mastocytosis (SM) is a disease characterized by increased mast cell burden and mediator release. Whether autoantibodies to type I interferon are present in the sera of patients with SM, and if so, whether they correlate with characteristics of disease, is unknown. The purpose of this study was to determine whether autoantibodies to type I interferons are observed in the sera of patients with SM, and if so, whether they correlate with biomarkers of disease severity. We analyzed sera from 89 patients with SM for concentrations of autoantibodies to type I interferon by using a multiplex particle-based assay and signal neutralization capacity by using a STAT1 activity assay and then compared these measurements with those in a database of information on 1284 healthy controls. Our cohort was predominantly female (57.3%), with a median age of 56 years. Of the cohort members, 13 produced autoantibodies to IFN-β, 3 to IFN-ω, and 0 to IFN-α. None of the 13 sera demonstrated signal neutralization. Neither autoantibody concentration nor signaling inhibition measurements correlated with tryptase concentrations or D816V allele burden. Although a small subpopulation of patients with SM have autoantibodies to type I interferons, there was no correlation between autoantibody production and signaling inhibition. These data are consistent with the conclusion that autoantibodies to type I interferon do not play a significant role in the pathogenesis or severity of SM.
AbstractList Autoantibodies to type I interferons have been identified in association with a variety of inflammatory and autoimmune diseases. Type I interferons have demonstrated inhibitory effects on mast cell proliferation and degranulation. Systemic mastocytosis (SM) is a disease characterized by increased mast cell burden and mediator release. Whether autoantibodies to type I interferon are present in the sera of patients with SM, and if so, whether they correlate with characteristics of disease, is unknown. The purpose of this study was to determine whether autoantibodies to type I interferons are observed in the sera of patients with SM, and if so, whether they correlate with biomarkers of disease severity. We analyzed sera from 89 patients with SM for concentrations of autoantibodies to type I interferon by using a multiplex particle-based assay and signal neutralization capacity by using a STAT1 activity assay and then compared these measurements with those in a database of information on 1284 healthy controls. Our cohort was predominantly female (57.3%), with a median age of 56 years. Of the cohort members, 13 produced autoantibodies to IFN-β, 3 to IFN-ω, and 0 to IFN-α. None of the 13 sera demonstrated signal neutralization. Neither autoantibody concentration nor signaling inhibition measurements correlated with tryptase concentrations or allele burden. Although a small subpopulation of patients with SM have autoantibodies to type I interferons, there was no correlation between autoantibody production and signaling inhibition. These data are consistent with the conclusion that autoantibodies to type I interferon do not play a significant role in the pathogenesis or severity of SM.
Autoantibodies to type I interferons have been identified in association with a variety of inflammatory and autoimmune diseases. Type I interferons have demonstrated inhibitory effects on mast cell proliferation and degranulation. Systemic mastocytosis (SM) is a disease characterized by increased mast cell burden and mediator release. Whether autoantibodies to type I interferon are present in the sera of patients with SM, and if so, whether they correlate with characteristics of disease, is unknown. The purpose of this study was to determine whether autoantibodies to type I interferons are observed in the sera of patients with SM, and if so, whether they correlate with biomarkers of disease severity. We analyzed sera from 89 patients with SM for concentrations of autoantibodies to type I interferon by using a multiplex particle-based assay and signal neutralization capacity by using a STAT1 activity assay and then compared these measurements with those in a database of information on 1284 healthy controls. Our cohort was predominantly female (57.3%), with a median age of 56 years. Of the cohort members, 13 produced autoantibodies to IFN-β, 3 to IFN-ω, and 0 to IFN-α. None of the 13 sera demonstrated signal neutralization. Neither autoantibody concentration nor signaling inhibition measurements correlated with tryptase concentrations or D816V allele burden. Although a small subpopulation of patients with SM have autoantibodies to type I interferons, there was no correlation between autoantibody production and signaling inhibition. These data are consistent with the conclusion that autoantibodies to type I interferon do not play a significant role in the pathogenesis or severity of SM.
Autoantibodies to type I interferons have been identified in association with a variety of inflammatory and autoimmune diseases. Type I interferons have demonstrated inhibitory effects on mast cell proliferation and degranulation. Systemic mastocytosis (SM) is a disease characterized by increased mast cell burden and mediator release. Whether autoantibodies to type I interferon are present in the sera of patients with SM, and if so, whether they correlate with characteristics of disease, is unknown.BackgroundAutoantibodies to type I interferons have been identified in association with a variety of inflammatory and autoimmune diseases. Type I interferons have demonstrated inhibitory effects on mast cell proliferation and degranulation. Systemic mastocytosis (SM) is a disease characterized by increased mast cell burden and mediator release. Whether autoantibodies to type I interferon are present in the sera of patients with SM, and if so, whether they correlate with characteristics of disease, is unknown.The purpose of this study was to determine whether autoantibodies to type I interferons are observed in the sera of patients with SM, and if so, whether they correlate with biomarkers of disease severity.ObjectiveThe purpose of this study was to determine whether autoantibodies to type I interferons are observed in the sera of patients with SM, and if so, whether they correlate with biomarkers of disease severity.We analyzed sera from 89 patients with SM for concentrations of autoantibodies to type I interferon by using a multiplex particle-based assay and signal neutralization capacity by using a STAT1 activity assay and then compared these measurements with those in a database of information on 1284 healthy controls.MethodsWe analyzed sera from 89 patients with SM for concentrations of autoantibodies to type I interferon by using a multiplex particle-based assay and signal neutralization capacity by using a STAT1 activity assay and then compared these measurements with those in a database of information on 1284 healthy controls.Our cohort was predominantly female (57.3%), with a median age of 56 years. Of the cohort members, 13 produced autoantibodies to IFN-β, 3 to IFN-ω, and 0 to IFN-α. None of the 13 sera demonstrated signal neutralization. Neither autoantibody concentration nor signaling inhibition measurements correlated with tryptase concentrations or D816V allele burden.ResultsOur cohort was predominantly female (57.3%), with a median age of 56 years. Of the cohort members, 13 produced autoantibodies to IFN-β, 3 to IFN-ω, and 0 to IFN-α. None of the 13 sera demonstrated signal neutralization. Neither autoantibody concentration nor signaling inhibition measurements correlated with tryptase concentrations or D816V allele burden.Although a small subpopulation of patients with SM have autoantibodies to type I interferons, there was no correlation between autoantibody production and signaling inhibition. These data are consistent with the conclusion that autoantibodies to type I interferon do not play a significant role in the pathogenesis or severity of SM.ConclusionAlthough a small subpopulation of patients with SM have autoantibodies to type I interferons, there was no correlation between autoantibody production and signaling inhibition. These data are consistent with the conclusion that autoantibodies to type I interferon do not play a significant role in the pathogenesis or severity of SM.
Background: Autoantibodies to type I interferons have been identified in association with a variety of inflammatory and autoimmune diseases. Type I interferons have demonstrated inhibitory effects on mast cell proliferation and degranulation. Systemic mastocytosis (SM) is a disease characterized by increased mast cell burden and mediator release. Whether autoantibodies to type I interferon are present in the sera of patients with SM, and if so, whether they correlate with characteristics of disease, is unknown. Objective: The purpose of this study was to determine whether autoantibodies to type I interferons are observed in the sera of patients with SM, and if so, whether they correlate with biomarkers of disease severity. Methods: We analyzed sera from 89 patients with SM for concentrations of autoantibodies to type I interferon by using a multiplex particle-based assay and signal neutralization capacity by using a STAT1 activity assay and then compared these measurements with those in a database of information on 1284 healthy controls. Results: Our cohort was predominantly female (57.3%), with a median age of 56 years. Of the cohort members, 13 produced autoantibodies to IFN-β, 3 to IFN-ω, and 0 to IFN-α. None of the 13 sera demonstrated signal neutralization. Neither autoantibody concentration nor signaling inhibition measurements correlated with tryptase concentrations or D816V allele burden. Conclusion: Although a small subpopulation of patients with SM have autoantibodies to type I interferons, there was no correlation between autoantibody production and signaling inhibition. These data are consistent with the conclusion that autoantibodies to type I interferon do not play a significant role in the pathogenesis or severity of SM.
ArticleNumber 100273
Author Lee, Serena J.
Rosen, Lindsey B.
Bai, Yun
Cao, Vivian
Holland, Steven M.
Komarow, Hirsh D.
Metcalfe, Dean D.
Author_xml – sequence: 1
  givenname: Vivian
  surname: Cao
  fullname: Cao, Vivian
  organization: Mast Cell Biology Section, Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md
– sequence: 2
  givenname: Serena J.
  surname: Lee
  fullname: Lee, Serena J.
  organization: Immunopathogenesis Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md
– sequence: 3
  givenname: Yun
  surname: Bai
  fullname: Bai, Yun
  organization: Mast Cell Biology Section, Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md
– sequence: 4
  givenname: Steven M.
  surname: Holland
  fullname: Holland, Steven M.
  organization: Immunopathogenesis Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md
– sequence: 5
  givenname: Lindsey B.
  surname: Rosen
  fullname: Rosen, Lindsey B.
  organization: Immunopathogenesis Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md
– sequence: 6
  givenname: Dean D.
  surname: Metcalfe
  fullname: Metcalfe, Dean D.
  organization: Mast Cell Biology Section, Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md
– sequence: 7
  givenname: Hirsh D.
  orcidid: 0000-0001-7012-9406
  surname: Komarow
  fullname: Komarow, Hirsh D.
  email: komarowh@niaid.nih.gov
  organization: Mast Cell Biology Section, Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38817344$$D View this record in MEDLINE/PubMed
BookMark eNp9kU9v1DAQxS1URMvST4CEcuSyW_9L7BwQqiqgKypxgbPlTMZbR0m82N6i_fa4TanaCyeP7De_55n3lpzMYUZC3jO6YZQ1F8NmsOB3G065LDeUK_GKnHGl-FrzVpw8q0_JeUoDLRqteEv5G3IqtGZKSHlGvl8ecrBz9l3oPaYqhyof91htKz9njA5jmFOpq73NHuecqj8-31bpmDJOHqrJphzgmEPy6R157eyY8PzxXJFfX7_8vLpe3_z4tr26vFmDaJlYO-ZQWaWV4xwa3SjVSykbC63jtoFaC9cq0UDLuo7z1nYIste1o5zXirFGrMh24fbBDmYf_WTj0QTrzcNFiDtjY_YwoqHUaVm8nHBC1tRZDX0NDeupaxEcFNbnhbU_dBP2UEaMdnwBffky-1uzC3eGMSZUrWQhfHwkxPD7gCmbySfAcbQzhkMygjbFWjdlrhURixRiSCmie_Jh1NzHagbzEKu5j9UssZauD8-_-NTzL8Qi-LQIsCz9zmM0CUpWgL2PCLlsxf_X4C-VX7cz
Cites_doi 10.1089/107999003321532475
10.1371/journal.pmed.0030289
10.1111/j.1440-1746.1989.tb01738.x
10.1126/science.abd4585
10.1159/000059404
10.1046/j.1365-2249.2003.02113.x
10.1056/NEJM199202273260907
10.1097/HS9.0000000000000646
10.1016/j.jdermsci.2009.08.006
10.1111/ejh.13875
10.1002/art.39607
10.1182/blood-2016-09-731893
10.1371/journal.pbio.3000530
10.1046/j.1365-2141.2002.03944.x
10.1016/j.jaip.2022.03.001
ContentType Journal Article
Copyright 2024
Copyright_xml – notice: 2024
DBID 6I.
AAFTH
NPM
AAYXX
CITATION
7X8
5PM
DOA
DOI 10.1016/j.jacig.2024.100273
DatabaseName ScienceDirect Open Access Titles
Elsevier:ScienceDirect:Open Access
PubMed
CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle PubMed
CrossRef
MEDLINE - Academic
DatabaseTitleList PubMed

MEDLINE - Academic

Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2772-8293
ExternalDocumentID oai_doaj_org_article_00f84a78f3f3450fa8cd5c61d0f9ecfc
10_1016_j_jacig_2024_100273
38817344
S2772829324000699
Genre Journal Article
GroupedDBID .1-
.FO
0SF
53G
6I.
AAFTH
AALRI
AAXUO
ADVLN
AFRHN
AITUG
AJUYK
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
EBS
FDB
GROUPED_DOAJ
M41
M~E
OK1
ROL
RPM
Z5R
AFJKZ
NPM
AAYXX
CITATION
7X8
5PM
ID FETCH-LOGICAL-c3913-f1fe7a787f22c68677d4446ac9f2a6c583f9736c91bb229abec4d85f022571163
IEDL.DBID RPM
ISSN 2772-8293
IngestDate Tue Oct 22 15:13:18 EDT 2024
Tue Sep 17 21:28:08 EDT 2024
Sat Oct 26 04:55:18 EDT 2024
Tue Oct 29 02:55:10 EDT 2024
Sat Nov 02 12:26:29 EDT 2024
Sat Aug 31 16:02:17 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords COVID-19
Autoantibodies
FI
autoimmune
mastocytosis
inflammatory
mast cell
cytokines
MCA
SM
type I interferons
Language English
License This is an open access article under the CC BY-NC-ND license.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3913-f1fe7a787f22c68677d4446ac9f2a6c583f9736c91bb229abec4d85f022571163
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
These first authors contributed equally to this work.
ORCID 0000-0001-7012-9406
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11137574/
PMID 38817344
PQID 3063458658
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_00f84a78f3f3450fa8cd5c61d0f9ecfc
pubmedcentral_primary_oai_pubmedcentral_nih_gov_11137574
proquest_miscellaneous_3063458658
crossref_primary_10_1016_j_jacig_2024_100273
pubmed_primary_38817344
elsevier_sciencedirect_doi_10_1016_j_jacig_2024_100273
PublicationCentury 2000
PublicationDate 2024-08-01
PublicationDateYYYYMMDD 2024-08-01
PublicationDate_xml – month: 08
  year: 2024
  text: 2024-08-01
  day: 01
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle The journal of allergy and clinical immunology. Global
PublicationTitleAlternate J Allergy Clin Immunol Glob
PublicationYear 2024
Publisher Elsevier Inc
Elsevier
Publisher_xml – name: Elsevier Inc
– name: Elsevier
References Casassus, Caillat-Vigneron, Martin, Simon, Gallais, Beaudry (bib8) 2002; 119
Slavikova, Schmeisser, Kontsekova, Mateicka, Borecky, Kontsek (bib1) 2003; 23
Bergman, Ramon, Wildbaum, Avitan-Hersh, Mayer, Shemer, Karin (bib4) 2009; 56
Sperr, Jordan, Fiegl, Escribano, Bellas, Dirnhofer (bib12) 2002; 128
Valent, Akin, Metcalfe (bib7) 2017; 129
Kobayashi, Shimabukuro-Demoto, Tsutsui, Toyama-Sorimachi (bib10) 2019; 17
Ikeda, Miyake, Toda, Yamada, Yamanaka, Oka (bib5) 1989; 4
Kluin-Nelemans, Jansen, Breukelman, Wolthers, Kluin, Kroon, Willemze (bib9) 1992; 326
Meager, Wadhwa, Dilger, Bird, Thorpe, Newsom-Davis, Willcox (bib2) 2003; 132
Graf, Herndlhofer, Kundi, Greiner, Sperr, Hadzijusufovic (bib15) 2023; 110
Valent, Akin, Hartmann, Alvarez-Twose, Brockow, Hermine (bib13) 2021; 5
Gupta, Tatouli, Rosen, Hasni, Alevizos, Manna (bib11) 2016; 68
Meager, Visvalingam, Peterson, Möll, Murumägi, Krohn (bib3) 2006; 3
Hoermann, Sotlar, Jawhar, Kristensen, Bachelot, Nedoszytko (bib14) 2022; 10
Bastard, Rosen, Zhang, Michailidis, Hoffmann, Zhang (bib6) 2020; 370
Meager (10.1016/j.jacig.2024.100273_bib3) 2006; 3
Bastard (10.1016/j.jacig.2024.100273_bib6) 2020; 370
Meager (10.1016/j.jacig.2024.100273_bib2) 2003; 132
Valent (10.1016/j.jacig.2024.100273_bib7) 2017; 129
Sperr (10.1016/j.jacig.2024.100273_bib12) 2002; 128
Gupta (10.1016/j.jacig.2024.100273_bib11) 2016; 68
Hoermann (10.1016/j.jacig.2024.100273_bib14) 2022; 10
Graf (10.1016/j.jacig.2024.100273_bib15) 2023; 110
Casassus (10.1016/j.jacig.2024.100273_bib8) 2002; 119
Bergman (10.1016/j.jacig.2024.100273_bib4) 2009; 56
Valent (10.1016/j.jacig.2024.100273_bib13) 2021; 5
Kobayashi (10.1016/j.jacig.2024.100273_bib10) 2019; 17
Ikeda (10.1016/j.jacig.2024.100273_bib5) 1989; 4
Kluin-Nelemans (10.1016/j.jacig.2024.100273_bib9) 1992; 326
Slavikova (10.1016/j.jacig.2024.100273_bib1) 2003; 23
References_xml – volume: 370
  year: 2020
  ident: bib6
  article-title: Autoantibodies against type I IFNs in patients with life-threatening COVID-19
  publication-title: Science
  contributor:
    fullname: Zhang
– volume: 326
  start-page: 619
  year: 1992
  end-page: 623
  ident: bib9
  article-title: Response to interferon alfa-2b in a patient with systemic mastocytosis
  publication-title: N Engl J Med
  contributor:
    fullname: Willemze
– volume: 5
  start-page: e646
  year: 2021
  ident: bib13
  article-title: Updated diagnostic criteria and classification of mast cell disorders: a consensus proposal
  publication-title: Hemasphere
  contributor:
    fullname: Hermine
– volume: 129
  start-page: 1420
  year: 2017
  end-page: 1427
  ident: bib7
  article-title: Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts
  publication-title: Blood
  contributor:
    fullname: Metcalfe
– volume: 68
  start-page: 1677
  year: 2016
  end-page: 1687
  ident: bib11
  article-title: Distinct Functions of autoantibodies against interferon in systemic lupus erythematosus: a comprehensive analysis of anticytokine autoantibodies in common rheumatic diseases
  publication-title: Arthritis Rheumatol
  contributor:
    fullname: Manna
– volume: 4
  start-page: 411
  year: 1989
  end-page: 418
  ident: bib5
  article-title: Detection of anti-interferon-alpha 2a antibodies in chronic liver disease
  publication-title: J Gastroenterol Hepatol
  contributor:
    fullname: Oka
– volume: 56
  start-page: 163
  year: 2009
  end-page: 167
  ident: bib4
  article-title: Psoriasis patients generate increased serum levels of autoantibodies to tumor necrosis factor-alpha and interferon-alpha
  publication-title: J Dermatol Sci
  contributor:
    fullname: Karin
– volume: 119
  start-page: 1090
  year: 2002
  end-page: 1097
  ident: bib8
  article-title: Treatment of adult systemic mastocytosis with interferon-α: results of a multicentre phase II trial on 20 patients
  publication-title: Br J Haematol
  contributor:
    fullname: Beaudry
– volume: 10
  start-page: 1953
  year: 2022
  end-page: 1963
  ident: bib14
  article-title: Standards of genetic testing in the diagnosis and prognostication of systemic mastocytosis in 2022: recommendations of the EU-US Cooperative Group
  publication-title: J Allergy Clin Immunol Pract
  contributor:
    fullname: Nedoszytko
– volume: 3
  start-page: e289
  year: 2006
  ident: bib3
  article-title: Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1
  publication-title: PLoS Med
  contributor:
    fullname: Krohn
– volume: 23
  start-page: 143
  year: 2003
  end-page: 147
  ident: bib1
  article-title: Incidence of autoantibodies against type I and type II interferons in a cohort of systemic lupus erythematosus patients in Slovakia
  publication-title: J Interferon Cytokine Res
  contributor:
    fullname: Kontsek
– volume: 128
  start-page: 136
  year: 2002
  end-page: 141
  ident: bib12
  article-title: Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease
  publication-title: Int Arch Allergy Immunol
  contributor:
    fullname: Dirnhofer
– volume: 110
  start-page: 67
  year: 2023
  end-page: 76
  ident: bib15
  article-title: Incidence of symptomatic Covid-19 infections in patients with mastocytosis and chronic myeloid leukemia: a comparison with the general Austrian population
  publication-title: Eur Jf Haematol
  contributor:
    fullname: Hadzijusufovic
– volume: 17
  year: 2019
  ident: bib10
  article-title: Type I interferon limits mast cell–mediated anaphylaxis by controlling secretory granule homeostasis
  publication-title: PLoS Biol
  contributor:
    fullname: Toyama-Sorimachi
– volume: 132
  start-page: 128
  year: 2003
  end-page: 136
  ident: bib2
  article-title: Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and/or myasthenia gravis
  publication-title: Clin Exp Immunol
  contributor:
    fullname: Willcox
– volume: 23
  start-page: 143
  year: 2003
  ident: 10.1016/j.jacig.2024.100273_bib1
  article-title: Incidence of autoantibodies against type I and type II interferons in a cohort of systemic lupus erythematosus patients in Slovakia
  publication-title: J Interferon Cytokine Res
  doi: 10.1089/107999003321532475
  contributor:
    fullname: Slavikova
– volume: 3
  start-page: e289
  year: 2006
  ident: 10.1016/j.jacig.2024.100273_bib3
  article-title: Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1
  publication-title: PLoS Med
  doi: 10.1371/journal.pmed.0030289
  contributor:
    fullname: Meager
– volume: 4
  start-page: 411
  year: 1989
  ident: 10.1016/j.jacig.2024.100273_bib5
  article-title: Detection of anti-interferon-alpha 2a antibodies in chronic liver disease
  publication-title: J Gastroenterol Hepatol
  doi: 10.1111/j.1440-1746.1989.tb01738.x
  contributor:
    fullname: Ikeda
– volume: 370
  year: 2020
  ident: 10.1016/j.jacig.2024.100273_bib6
  article-title: Autoantibodies against type I IFNs in patients with life-threatening COVID-19
  publication-title: Science
  doi: 10.1126/science.abd4585
  contributor:
    fullname: Bastard
– volume: 128
  start-page: 136
  year: 2002
  ident: 10.1016/j.jacig.2024.100273_bib12
  article-title: Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease
  publication-title: Int Arch Allergy Immunol
  doi: 10.1159/000059404
  contributor:
    fullname: Sperr
– volume: 132
  start-page: 128
  year: 2003
  ident: 10.1016/j.jacig.2024.100273_bib2
  article-title: Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and/or myasthenia gravis
  publication-title: Clin Exp Immunol
  doi: 10.1046/j.1365-2249.2003.02113.x
  contributor:
    fullname: Meager
– volume: 326
  start-page: 619
  year: 1992
  ident: 10.1016/j.jacig.2024.100273_bib9
  article-title: Response to interferon alfa-2b in a patient with systemic mastocytosis
  publication-title: N Engl J Med
  doi: 10.1056/NEJM199202273260907
  contributor:
    fullname: Kluin-Nelemans
– volume: 5
  start-page: e646
  year: 2021
  ident: 10.1016/j.jacig.2024.100273_bib13
  article-title: Updated diagnostic criteria and classification of mast cell disorders: a consensus proposal
  publication-title: Hemasphere
  doi: 10.1097/HS9.0000000000000646
  contributor:
    fullname: Valent
– volume: 56
  start-page: 163
  year: 2009
  ident: 10.1016/j.jacig.2024.100273_bib4
  article-title: Psoriasis patients generate increased serum levels of autoantibodies to tumor necrosis factor-alpha and interferon-alpha
  publication-title: J Dermatol Sci
  doi: 10.1016/j.jdermsci.2009.08.006
  contributor:
    fullname: Bergman
– volume: 110
  start-page: 67
  year: 2023
  ident: 10.1016/j.jacig.2024.100273_bib15
  article-title: Incidence of symptomatic Covid-19 infections in patients with mastocytosis and chronic myeloid leukemia: a comparison with the general Austrian population
  publication-title: Eur Jf Haematol
  doi: 10.1111/ejh.13875
  contributor:
    fullname: Graf
– volume: 68
  start-page: 1677
  year: 2016
  ident: 10.1016/j.jacig.2024.100273_bib11
  article-title: Distinct Functions of autoantibodies against interferon in systemic lupus erythematosus: a comprehensive analysis of anticytokine autoantibodies in common rheumatic diseases
  publication-title: Arthritis Rheumatol
  doi: 10.1002/art.39607
  contributor:
    fullname: Gupta
– volume: 129
  start-page: 1420
  year: 2017
  ident: 10.1016/j.jacig.2024.100273_bib7
  article-title: Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts
  publication-title: Blood
  doi: 10.1182/blood-2016-09-731893
  contributor:
    fullname: Valent
– volume: 17
  year: 2019
  ident: 10.1016/j.jacig.2024.100273_bib10
  article-title: Type I interferon limits mast cell–mediated anaphylaxis by controlling secretory granule homeostasis
  publication-title: PLoS Biol
  doi: 10.1371/journal.pbio.3000530
  contributor:
    fullname: Kobayashi
– volume: 119
  start-page: 1090
  year: 2002
  ident: 10.1016/j.jacig.2024.100273_bib8
  article-title: Treatment of adult systemic mastocytosis with interferon-α: results of a multicentre phase II trial on 20 patients
  publication-title: Br J Haematol
  doi: 10.1046/j.1365-2141.2002.03944.x
  contributor:
    fullname: Casassus
– volume: 10
  start-page: 1953
  year: 2022
  ident: 10.1016/j.jacig.2024.100273_bib14
  article-title: Standards of genetic testing in the diagnosis and prognostication of systemic mastocytosis in 2022: recommendations of the EU-US Cooperative Group
  publication-title: J Allergy Clin Immunol Pract
  doi: 10.1016/j.jaip.2022.03.001
  contributor:
    fullname: Hoermann
SSID ssj0002872902
Score 2.3156095
Snippet Autoantibodies to type I interferons have been identified in association with a variety of inflammatory and autoimmune diseases. Type I interferons have...
Background: Autoantibodies to type I interferons have been identified in association with a variety of inflammatory and autoimmune diseases. Type I interferons...
SourceID doaj
pubmedcentral
proquest
crossref
pubmed
elsevier
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 100273
SubjectTerms Autoantibodies
autoimmune
Brief Report
COVID-19
cytokines
inflammatory
mast cell
mastocytosis
type I interferons
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1NT9wwFLQqDqgXBLRAyodcqUci4q_YPgIC0Vb0VCRuluPYkJVIqt3sof--z3GWbkCil96iJEriGTtvnv0yQeiLYCG6rMNA0sLlnNQ-t9zXeWBaVM4Vntj4gfPtj_Lmjn-7F_drv_qKNWHJHjgBd1YUQXErVWCBcVEEq1wtXEnqImjvghvevgVdS6Zmw5QRiMZYunP4t6BrZl3zABkh5YPvqGSTUDQ49k8i0mvF-bJwci0SXW-jrVFC4vP06DvonW930ebtuEj-AX0_X_YdANZUXSwRxH2H40Qr_oqjN8Q8-Dn0NNjGo6fqAsfJWJw8nRuHnywIQve77xbN4iO6u776eXmTj_9MyB3ThOWBBC8BLhkodWU0q6s5ZHzW6UBt6YRiQUtWOk2qilJtgUJeKxEglAtJQJztoY22a_0Bwk4LK1RpqSSB19JXkBwVlknvS2qJtBk6XcFnfiVrDLOqGZuZAW0T0TYJ7QxdRIifT42-1sMOYNuMbJt_sZ2hckWQGSVCCv1wqebtu39e0WlgAMVVEdv6brkwkDPBrRQosQztJ3qfn5EpRSTjPENqQvykEdMjbfM4mHRDDGFSSP7pfzT7EL2PbUmFh0doo58v_TGIob46Gfr9HwDnCks
  priority: 102
  providerName: Directory of Open Access Journals
Title Autoantibodies to type I interferons in patients with systemic mastocytosis
URI https://dx.doi.org/10.1016/j.jacig.2024.100273
https://www.ncbi.nlm.nih.gov/pubmed/38817344
https://www.proquest.com/docview/3063458658
https://pubmed.ncbi.nlm.nih.gov/PMC11137574
https://doaj.org/article/00f84a78f3f3450fa8cd5c61d0f9ecfc
Volume 3
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELbaHhAXxJvQUhmJI-nG8ftYKqoCWsSBSr1ZjmOXrNik2s0e-PcdO0lpQOLALcrL9sxY8_Dnzwi94zRElnWYSJq7nJHa55b5Og9U88q5whMbNzgvv4qLS_b5il_tITHthUmgfVc1J-3P9Unb_EjYypu1W0w4scW35Vk8Hl1yyRb7aB_8770cfZXKRRAwRtjO4W8w18q65hqywZIlzlFJZ24osfXPvNHf0eafoMl7Xuj8MXo0ho_4dOjmE7Tn26fowXJcIH-Gvpzu-g6E1VRdhAfivsOxyIo_4cgLsQl-A1YG13jkU93iWIjFA59z4_DaQjDofvXdttk-R5fnH7-fXeTjeQm5o5rQPJDgpYUZGMrSiUhUVzPI9qzTobTCcUWDllQ4TaqqLLUF9bFa8QBunEsCgdkLdNB2rX-FsNPcciVsKUlgtfQVJEaFpdJ7UVoibYbeT-IzNwMthpnwYiuTpG2itM0g7Qx9iCK-ezVyWqcb3ebajJo1RREUg-4HGijjRbDK1dwJUhdBexdchsSkIDOGB4Pbh181_2797aROA5MnrojY1ne7rYF8CZpSEIVl6OWg3rs-UqWIpIxlSM0UPxvE_AnYayLonuzz9f9_eogexhEMUMMjdNBvdv4NhD99dZzKBsfJ5m8BjakJKA
link.rule.ids 230,314,727,780,784,864,885,2102,27924,27925,53791,53793
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIgEXxJtQHkbiSLpxbMfxsVRUW9qtOLRSb5bj2G1WbFLtZg_8e8Z5lAYkDtyivGzP2Jpv7M-fAT4J5oPKOg4kJWzMaeliw10Ze6ZEYW3iqAkbnBdn2fyCf7sUlzuQjXthOtK-Lar9-sdqv66uO27lzcrORp7Y7PviMByPLoXks3twXzCp6J0sfdlNGCFkDMSdvd90rqWx1RXmgynvVEclmwSiTq9_Eo_-xpt_0ibvxKGjJ_B4AJDkoK_oU9hx9TN4sBiWyJ_DycG2bdBcVdEEgiBpGxKmWckxCcoQa-_W2M_wmgyKqhsSpmJJr-hcWbIyCAftz7bZVJsXcHH09fxwHg8nJsSWKcpiT72TBsegT1ObBam6kmO-Z6zyqcmsyJlXkmVW0aJIU2XQgbzMhcdALiRFaPYSduumdq-BWCWMyDOTSup5KV2BqVFimHQuSw2VJoLPo_n0TS-MoUfG2FJ31tbB2rq3dgRfgolvXw2q1t2NZn2lB9_qJPE5x-p75hkXiTe5LYXNaJl45ay3EWSjg_QAEPrAj7-q_l36x9GdGodPWBMxtWu2G40ZExaVIw6L4FXv3ts6sjynknEeQT5x_KQR0yfYYzuJ7rGHvvn_Tz_Aw_n54lSfHp-d7MGj0JqeePgWdtv11r1DMNQW77ue_wtefwuI
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELagSBUXRHmGQjESR9KNYzu2j6XtqqVs1QOVerMcxy5Zsclqkz3w7xnnURqQOHCL8rRnxppv7C-fEfrIqQ8q6zCQFLcxI4WLDXNF7KniubWJIyb84Ly4zM6u2ZcbfjOwKpuBVlnZvDysfqwOq_J7x61cr-xs5InNrhbHYXt0wQWbrQs_e4gecQpRdq9SX3aTRgAbA3ln_zela2lseQs1Yco65VFBJ8mo0-yf5KS_Meef1Ml7uWj-FD0ZQCQ-6hu7hx646hnaXQzL5M_RxdG2rcFkZV4HkiBuaxymWvE5DuoQG-82EGtwjAdV1QaH6VjcqzqXFq8MQEL7s62bsnmBruen347P4mHXhNhSRWjsiXfCwDj0aWqzIFdXMKj5jFU-NZnlknolaGYVyfM0VQacyArJPSRzLgjAs5dop6or9xphq7jhMjOpIJ4VwuVQHiWGCuey1BBhIvRpNJ9e9-IYemSNLXVnbR2srXtrR-hzMPHdrUHZujtRb2714F-dJF4yaL6nnjKeeCNtwW1GisQrZ72NUDY6SA8goU_-8Kry31__MLpTwxAK6yKmcvW20VA1wackYLEIverde9dGKiURlLEIyYnjJ52YXoGo7WS6xyh98_-Pvke7Vydz_fX88mIfPQ6d6bmHb9FOu9m6d4CH2vygC_xfJpkMmw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Autoantibodies+to+type+I+interferons+in+patients+with+systemic+mastocytosis&rft.jtitle=The+journal+of+allergy+and+clinical+immunology.+Global&rft.au=Cao%2C+Vivian&rft.au=Lee%2C+Serena+J&rft.au=Bai%2C+Yun&rft.au=Holland%2C+Steven+M&rft.date=2024-08-01&rft.eissn=2772-8293&rft.volume=3&rft.issue=3&rft.spage=100273&rft_id=info:doi/10.1016%2Fj.jacig.2024.100273&rft_id=info%3Apmid%2F38817344&rft.externalDocID=38817344
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2772-8293&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2772-8293&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2772-8293&client=summon